Bottom line
LABU vs HIBS: the short answer
LABU (Direxion Daily S&P Biotech Bull 3X ETF) and HIBS (Direxion Daily S&P 500(R) High Beta Bear 3X ETF) share a meaningful slice of their top holdings — about 47% by weight.
But LABU is far broader, holding 163 positions to 8 for HIBS, so beyond the top names it adds exposure HIBS doesn't have.
LABU is cheaper at 0.96% vs 1.06% — a difference of $10 a year per $10,000 invested.
Over five years, LABU returned −39.6% a year vs −55.6% for HIBS.
Updated Nov 19, 2026
LABU vs HIBS side by side
| LABU | HIBS | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.96% | 1.06% |
| Annual cost per $10k | $96 | $106 |
| 10-yr cost on $10k (prospectus) | $1,178 | $1,347 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +78.7% | −72.4% |
| 5-yr return (annualized) | −39.6% | −55.6% |
| 10-yr return (annualized) | −20.8% | — |
| Best quarter | +161.5% | +74.7% |
| Worst quarter | −67.4% | −79.0% |
| Net assets (fund) | $494.4M | $22.6M |
| Number of holdings | 163 | 8 |
| Portfolio turnover | 107% | % |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LABU | HIBS | Difference |
|---|---|---|---|
| 2025 | +78.7% | −72.4% | +151.1% |
| 2024 | −25.9% | −26.6% | +0.7% |
| 2023 | −13.4% | −63.0% | +49.5% |
| 2022 | −80.3% | −7.6% | −72.7% |
| 2021 | −64.3% | −75.2% | +10.9% |
| 2020 | +74.7% | −91.6% | +166.3% |
Source: Fund prospectus bar charts
Holdings overlap
7 of LABU's top 25 holdings also appear in HIBS's top 8.
| Holding | LABU | HIBS |
|---|---|---|
| Dreyfus | 15.86% | 48.43% |
| Goldman Financial | 14.83% | 28.96% |
| N/a | 9.63% | 1.18% |
| N/a | 7.30% | 1.18% |
| Goldman Sachs Liq Es Fd A | 5.35% | 26.65% |
| N/a | 4.85% | 1.18% |
| N/a | 3.87% | 1.18% |
Source: SEC Form N-PORT
LABU top 10
- Dreyfus — 15.86%
- Goldman Financial — 14.83%
- N/a — 9.63%
- N/a — 7.30%
- Goldman Sachs Liq Es Fd A — 5.35%
- N/a — 4.85%
- N/a — 3.87%
- Apogee Therapeutics Inc — 1.11%
- Oruka Therapeutics Inc — 1.03%
- Dianthus Therapeutics Inc — 0.96%
HIBS top 10
- Dreyfus — 48.43%
- Goldman Financial — 28.96%
- Goldman Sachs Liq Es Fd A — 26.65%
- N/a — 5.90%
- N/a — 2.40%
- N/a — 2.21%
- N/a — 1.19%
- N/a — 1.18%
FAQ
What is the difference between LABU and HIBS?
Which is cheaper, LABU or HIBS?
Should I own both LABU and HIBS?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.